Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

Abstract: A pseudo wire label reflector, based on a existing label distribution router, further includes: a mode management unit, for determining the mode for switching and transferring a pseudo wire label message; a first session management unit, for saving the support information that LDP signaling session connection supports the pseudo wire label reflecting capacity; a first pseudo wire label receiving unit, for receiving a pseudo wire label message; a first pseudo wire management unit, for saving the switched pseudo wire state and deciding whether to modify the pseudo wire label message according to the switch and transfer mode determined by the mode management unit; a first pseudo wire label sending unit, for sending the pseudo wire label message. The invention also provides an edge apparatus and a L2 VPN.

Abstract: A pseudo wire label reflector, based on a existing label distribution router, further includes: a mode management unit, for determining the mode for switching and transferring a pseudo wire label message; a first session management unit, for saving the support information that LDP signaling session connection supports the pseudo wire label reflecting capacity; a first pseudo wire label receiving unit, for receiving a pseudo wire label message; a first pseudo wire management unit, for saving the switched pseudo wire state and deciding whether to modify the pseudo wire label message according to the switch and transfer mode determined by the mode management unit; a first pseudo wire label sending unit, for sending the pseudo wire label message. The invention also provides an edge apparatus and a L2 VPN.

Abstract: This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.

Abstract: This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.

Abstract: This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.

Abstract: A pseudo wire label reflector, based on a existing label distribution router, further includes: a mode management unit, for determining the mode for switching and transferring a pseudo wire label message; a first session management unit, for saving the support information that LDP signaling session connection supports the pseudo wire label reflecting capacity; a first pseudo wire label receiving unit, for receiving a pseudo wire label message; a first pseudo wire management unit, for saving the switched pseudo wire state and deciding whether to modify the pseudo wire label message according to the switch and transfer mode determined by the mode management unit; a first pseudo wire label sending unit, for sending the pseudo wire label message. The invention also provides an edge apparatus, a L2 VPN and a method for providing pseudo wire service in PSN.

Abstract: A pseudo wire label reflector, based on a existing label distribution router, further includes: a mode management unit, for determining the mode for switching and transferring a pseudo wire label message; a first session management unit, for saving the support information that LDP signaling session connection supports the pseudo wire label reflecting capacity; a first pseudo wire label receiving unit, for receiving a pseudo wire label message; a first pseudo wire management unit, for saving the switched pseudo wire state and deciding whether to modify the pseudo wire label message according to the switch and transfer mode determined by the mode management unit; a first pseudo wire label sending unit, for sending the pseudo wire label message. The invention also provides an edge apparatus, a L2 VPN and a method for providing pseudo wire service in PSN.

Abstract: The present invention provides nucleotides, peptides, HCV mutants, and cell lines containing mutations associated with drug resistance. In addition, the present invention provides methods for screening for therapeutic compounds capable of inhibiting HCV as well as methods for inhibiting HCV, e.g., by targeting specific binding sites associated with HCV drug resistance.

Abstract: Various 2?-modified nucleoside analogs and corresponding prodrugs are provided, and particularly contemplated methods of use include use as antiviral agents, and especially as antiviral agents against HCV.

Abstract: This invention concerns certain 5-(substituted amino) isothiazoles, compounds of Formula I, and salts thereof, where Q is CN, NHCONRaRb, or CONRaRb, where Ra and Rb are defined herein; and R1 is cyclohexyl, adamantan-1-yl, indan-1-yl, phenyl, benzyl, pyridyl, pyridylmethyl, or pyrimidyl, where all aromatic R1 groups are optionally substituted, provided that when R1 is phenyl, then R1 bears at least one non-alkyl substituent, and further provided that R1 is not 4-chloro-3-trichloromethyl-phenyl; The invention also concerns the tautomeric 5-(substituted amino)-isothiazol-3(2H)-ones, and the use of such compounds to treat Hepatitis C infection. It also concerns thiocarbamoyl acetamides, which are synthetic precursors to the isothiazoles.

Abstract: Contemplated dinucleotide compounds have a general structure of A-B and inhibit synthesis of an RNA-dependent polymerase that initiates RNA replication de novo. In preferred dinucleotides, A comprises a purine or modified purine heterocyclic base and B comprises a pyrimidine or modified pyrimidine heterocyclic base.

Abstract: This invention provides efficient HCV replicase complexes comprising novel RNA template and primer pair. Assay systems are also provided, which use such complexes, for detecting replicase activity, quantitatively studying the kinetics and mechanism of HCV NS5B-catalyzed nucleotide incorporation, and identifying inhibitors of HCV replicase. The assay systems use small and well-defined synthetic RNAs which allow efficient assembly of all catalytic components in the quaternary complex for HCV NS5B-directed RNA replication. Specific template-primer requirements for efficient RNA synthesis by HCV NS5B replicase are provided for use in assay systems.

Abstract: This invention provides efficient HCV replicase complexes comprising novel RNA template and primer pair. Assay systems are also provided, which use such complexes, for detecting replicase activity, quantitatively studying the kinetics and mechanism of HCV NS5B-catalyzed nucleotide incorporation, and identifying inhibitors of HCV replicase. The assay systems use small and well-defined synthetic RNAs which allow efficient assembly of all catalytic components in the quaternary complex for HCV NS5B-directed RNA replication. Specific template-primer requirements for efficient RNA synthesis by HCV NS5B replicase are provided for use in assay systems.

Abstract: The present invention relates to identification of the features of an RNA template that provide for efficient “copy-back” self-priming activity of hepatitis C virus replicase. This activity can be used to screen for anti-HCV replicase compounds, or to characterize the biological relevance of lead compounds that have already been identified. The specific features of the optimal RNA templates can be used for developing a system to characterize HCV NS5B polymerase mechanistically and kinetically, and for designing small RNA molecules to co-crystallize with HCV NS5B polymerase.

Abstract: This invention relates to nucleic acids encoding HCV/GBV-B constructs and chimeric, infectious HCV/GBV-B viruses that comprise a non-structural (NS) protein function of hepatitis C virus (HCV). The invention further relates to methods for using the nucleic acid constructs and chimeric, infectious viruses to screen for HCV inhibitors in cell culture models or in animal models of viral infection.

Abstract: The present invention relates to identification of a novel, de novo priming activity of hepatitis C virus replicase. This activity can be used to screen for anti-HCV replicase compounds, or to characterize the biological relevance of lead compounds that have already been identified.

Abstract: Disclosed are screening methods to identify molecules which activate or inhibit the activity of an ATPase protein of the Flaviviridae family, particularly NS4B protein of Hepatitis C Virus (HCV). These inhibitors and activators of HCV NS4B protein potentially can be used as antiviral compounds and as therapeutic agents for the treatment of viruses linked to the Flaviviridae family, particularly HCV, flaviviruses such as yellow fever virus, Dengue virus types 1-4, and pestiviruses such as bovine viral diarrhea virus and classic swine fever, among others.

Abstract: Isolated human herpesvirus type 8 nucleic acid sequences expressed in latently infected human cells including primary Kaposi's sarcoma cells, primary pulmonary tumor cells, and a body cavity based lymphoma cell line are disclosed. Methods of detecting HHV-8 infection and methods of inhibiting expression of the nucleic acid sequences in vivo are also disclosed.